Post-transplant immunotherapy designed to prevent cancer recurrence

Pediatr Transplant. 1999:3 Suppl 1:96-101. doi: 10.1034/j.1399-3046.1999.00064.x.

Abstract

Most stem cell transplants are performed to treat neoplasms. Yet many patients survive the transplant but die from cancer recurrence post-transplant. The incorporation of post-transplant immunotherapy offers the potential for enhanced antitumor efficacy.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Bone Marrow Transplantation / adverse effects
  • Bone Marrow Transplantation / methods*
  • Child
  • Child, Preschool
  • Female
  • Graft vs Tumor Effect / immunology*
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunotherapy*
  • Killer Cells, Natural / immunology*
  • Lymphocyte Activation
  • Male
  • Neoplasm Recurrence, Local / prevention & control*
  • Prognosis
  • Survival Rate
  • Transplantation, Autologous
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Immunosuppressive Agents